[Ip-health] Save the Date - 6 December 2018 - Implications of Article 27.3(a) of the WTO TRIPS Agreement on the patentability of gene and cell-based therapies

Thiru Balasubramaniam thiru at keionline.org
Sat Dec 1 01:11:31 PST 2018


DATE: Thursday, 6 December 2018
TIME: 1:30 PM to 3 PM
CONVENER: Knowledge Ecology International (KEI)

Knowledge Ecology International (KEI) cordially invites you to attend our
side event during negotiations of the 29th Session of the Standing
Committee on the Law of Patents (SCP) of the World Intellectual Property
Organization (WIPO).

This panel discussion will examine the implications of Article 27.3(a) of
the TRIPS Agreement on the patentability of gene- and cell-based therapies
including those involving autologous T-cell immunotherapy (CAR T), CRISPR
and other technologies when treatment can be described as a service or a
medical procedure, rather than a product. Panelists will explore if certain
cell- and gene-based treatments are, in fact, exempt from patentability
when a country has an exception that mirrors Article 27.3(a) of the TRIPS
Agreement. Panelists will also discuss non-patent approaches to providing
incentives to invest in innovations that delink R&D costs from prices and
monopolies on the medical technologies for such treatments, for example
innovation inducement prize funds and market entry rewards.

James Love, Knowledge Ecology International, Director
Jayashree Watal, World Trade Organization, Counsellor, Intellectual
Property Division
Dr. Els Torreele, Médecins Sans Frontières, Access Campaign, Executive

Thiru Balasubramaniam
Geneva Representative
Knowledge Ecology International
41 22 791 6727
thiru at keionline.org

More information about the Ip-health mailing list